Merck KGaA (OTCMKTS:MKGAF – Get Free Report) is projected to issue its results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of $2.47 per share and revenue of $6.20 billion for the quarter.
Merck KGaA Stock Performance
Shares of MKGAF stock opened at $167.57 on Thursday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31. The firm has a market capitalization of $21.66 billion, a price-to-earnings ratio of 25.58 and a beta of 0.96. Merck KGaA has a one year low of $116.68 and a one year high of $175.56. The company has a 50 day moving average price of $160.41 and a 200 day moving average price of $151.75.
About Merck KGaA
Merck KGaA is a German science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The company operates under the name EMD Serono in the United States and Canada, where the Merck name is associated with a separate company.
Merck KGaA operates through three primary business sectors: Healthcare, Life Science and Electronics. Its Healthcare business develops and markets prescription medicines, including treatments in oncology, neurology and immunology, as well as fertility and other specialty-care products.
Read More
- Five stocks we like better than Merck KGaA
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
